290 related articles for article (PubMed ID: 26259990)
1. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
[TBL] [Abstract][Full Text] [Related]
2. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
5. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
Loquai C; Nashan D; Metze D; Beiteke U; Rüping KW; Luger TA; Grabbe S
Hautarzt; 2004 Feb; 55(2):176-81. PubMed ID: 14968329
[TBL] [Abstract][Full Text] [Related]
6. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
[TBL] [Abstract][Full Text] [Related]
7. T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma.
Ogawa H; Luxardi G; Kirane A; Kulkarni R; Monjazeb AM; Cheng MY; Ma C; Maverakis E
J Invest Dermatol; 2018 Jun; 138(6):1442-1445. PubMed ID: 29291382
[No Abstract] [Full Text] [Related]
8. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
9. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
[TBL] [Abstract][Full Text] [Related]
10. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
Miller AK; Dusing R; Meggison A; Aires D
J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
[TBL] [Abstract][Full Text] [Related]
11. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
[TBL] [Abstract][Full Text] [Related]
12. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
Ellis LZ; Cohen JL; High W; Stewart L
Dermatol Surg; 2012 Jun; 38(6):937-46. PubMed ID: 22338583
[TBL] [Abstract][Full Text] [Related]
13. Using topical imiquimod for the management of positive in situ margins after melanoma resection.
Pandit AS; Geiger EJ; Ariyan S; Narayan D; Choi JN
Cancer Med; 2015 Apr; 4(4):507-12. PubMed ID: 25620351
[TBL] [Abstract][Full Text] [Related]
14. Treatment of locally metastatic melanoma: a novel approach.
Shistik G; Prakash AV; Fenske NA; Glass LF
J Drugs Dermatol; 2007 Aug; 6(8):830-2. PubMed ID: 17763615
[TBL] [Abstract][Full Text] [Related]
15. Metastatic melanoma - a review of current and future treatment options.
Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
Park AJ; Paul J; Chapman MS; Samie FH
Dermatol Surg; 2017 Aug; 43(8):1017-1022. PubMed ID: 28328708
[TBL] [Abstract][Full Text] [Related]
17. Local cryosurgery and imiquimod: A successful combination for the treatment of locoregional cutaneous metastasis of melanoma: A case series.
Rivas-Tolosa N; Ortiz-Brugués A; Toledo-Pastrana T; Baradad M; Traves V; Soriano V; Sanmartín V; Requena C; Martí R; Nagore E
J Dermatol; 2016 May; 43(5):553-6. PubMed ID: 26660713
[TBL] [Abstract][Full Text] [Related]
18. [In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery].
Elfatoiki FZ; Longvert C; Clerici T; Bourgault-Villada I; Roudier-Pujol C; Vasseur E; Saiag P
Ann Dermatol Venereol; 2014 Feb; 141(2):106-10. PubMed ID: 24507204
[TBL] [Abstract][Full Text] [Related]
19. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].
Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W
Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
